The Medicine Cabinet as a Signalling Laboratory: Five Familiar Drugs with Cellular Jobs

Cell signalling can feel like an abstract topic — a tangle of receptors, second messengers and phosphorylation events confined to lecture slides. Yet millions of people across the UK take medicines every day that do nothing except manipulate these pathways. The medicine cabinet is, in effect, a small applied signalling laboratory. Here are five familiar prescriptions, and the cellular conversations they quietly reshape.

1. Beta Blockers: Turning Down the Volume on Adrenaline

Propranolol, atenolol and bisoprolol are among the most commonly prescribed drugs in Britain, dispensed for hypertension, angina and arrhythmias. Their target is the beta-adrenergic receptor, a G-protein coupled receptor (GPCR) that normally binds adrenaline released during stress or exercise.

Under normal conditions, adrenaline binding activates a Gs protein, which in turn stimulates adenylyl cyclase to produce the second messenger cyclic AMP. In cardiac muscle, rising cAMP activates protein kinase A, which phosphorylates calcium channels and speeds up both heart rate and contractility. A beta blocker occupies the receptor without activating it, so the cascade is never triggered. The result is a heart that beats more slowly and with less force — pharmacology as a judicious mute button on one of the body's loudest signalling channels.

2. SSRIs: A Lesson in Recycler Biology

Selective serotonin reuptake inhibitors — sertraline, citalopram and fluoxetine are widely prescribed by GPs — act not on a receptor but on a transporter. After serotonin is released into a synapse, the serotonin transporter (SERT) pumps it back into the presynaptic neuron, ending the signal.

SSRIs block that reuptake. Serotonin lingers longer in the synaptic cleft, prolonging its signalling at postsynaptic receptors. Interestingly, the therapeutic benefit takes weeks to develop, long after transporter blockade begins. The prevailing explanation involves receptor adaptation: chronic exposure causes postsynaptic receptors to desensitise and downstream signalling to re-equilibrate. It is a useful reminder that signalling systems respond to sustained change with compensatory reprogramming, not instant adjustment.

3. Statins: Blocking the Signal's Raw Materials

Atorvastatin and simvastatin are prescribed to millions of people in the UK for cardiovascular risk reduction. Their molecular target is HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway.

That pathway does more than make cholesterol. It also generates isoprenoid lipids used to anchor signalling proteins — including RAS and Rho GTPases — to the inner face of the plasma membrane. Without this lipid anchor, these small G-proteins cannot localise properly or transmit their signals. Statins therefore dampen cholesterol production and subtly impair a family of membrane signalling proteins, an overlap that helps explain some of their effects beyond lipid lowering.

4. Salbutamol: A Signalling Shortcut in Reverse

The blue reliever inhaler carried by people with asthma works through the same pathway beta blockers interrupt — but in the opposite direction. Salbutamol is a beta-2 adrenergic agonist: it binds receptors on airway smooth muscle and activates Gs, cAMP and protein kinase A. PKA phosphorylation relaxes the muscle, opening the airway within minutes. Where propranolol silences the pathway, salbutamol amplifies it — a neat pair of examples showing that direction of effect depends entirely on which receptor subtype is targeted.

5. Omeprazole: Controlling the Signal at the Source

Rounding out the list, the proton pump inhibitor omeprazole — available on prescription and in UK pharmacies — is best understood as a signal blocker at the final step. Histamine released from enterochromaffin-like cells binds H2 receptors on gastric parietal cells, triggering cAMP signalling that inserts the H+/K+ ATPase pump into the cell membrane. Omeprazole does not touch the receptor or the second messenger; it disables the pump itself, the terminal effector of the cascade. Stomach acid secretion stops, regardless of what signals arrive upstream.

The Bigger Picture

What unites these five medicines is a shared principle: disease can be treated by adjusting signalling, and the adjustment can happen at any point in the chain — receptor, transporter, enzyme, or effector. For A-level and first-year undergraduate students, the medicine cabinet offers proof that the pathway diagrams are not merely academic. Every prescription dispensed by the NHS is a hypothesis about cell communication, tested daily on a national scale.